Clinical trial
Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin and…
NCT00189410 · AGO Study Group, Other · Completed
Key facts
| NCT number | NCT00189410 |
|---|---|
| Title | Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin and Carboplatin in Malignant Gynecologic Tumours |
| Official title | Phase II Trial With Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin (PLD) and Carboplatin in Malignant Gynecologic Tumour's |
| Lead sponsor | AGO Study Group, Other |
| Collaborators | MedServ. GmbH, Wiesbaden Essex Pharma GmbH Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cancer of the Ovary Treated as 2nd Line Therapy, Muellerian Mixed Tumours, Tumours of the Uterus, Cervical Cancers, Non-Epithelial Ovarian Tumours |
| Intervention type | Drug |
| Interventions | Pegylated Liposomal Doxorubicin and Carboplatin |
| Enrollment | 140 |
| Start date | Jun 1, 2003 |
| Primary completion | Sep 1, 2005 |
| Completion | Sep 1, 2006 |
| First posted | Sep 19, 2005 |
| Last update posted | Jul 20, 2010 |
| Countries | Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: